Mechanisms of disease: pulmonary arterial hypertension

DOI: 10.1038/nrcardio.2011.87
Nature Reviews Cardiology, 2011, 8, 443-55.

#	Paper	IF	Citations
552	Circulating cytokines and growth factors in pediatric pulmonary hypertension. **2012**, 2012, 143428		27
551	Pulmonary hypertension: the science behind the disease spectrum. **2012**, 21, 19-26		61
550	The role of endoplasmic reticulum stress and the unfolded protein response in fibrosis. **2012**, 24, 663-8		89
549	TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. **2012**, 13, 375-86		23
548	Animal models of pulmonary hypertension: Rho kinase inhibition. **2012**, 109, 67-75		17
547	Pathobiology of pulmonary arterial hypertension and right ventricular failure. **2012**, 40, 1555-65		195
546	Tadalafil for the treatment of pulmonary arterial hypertension. **2012**, 13, 747-55		13
545	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. **2012**, 7, e43433		89
544	Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. **2013**, 188, 482-91		33
543	Riociguat for the treatment of pulmonary arterial hypertension. **2013**, 369, 330-40		861
542	Metabolic syndrome and right ventricle: an updated review. **2013**, 24, 608-16		16
541	Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tract. **2013**, 305, L205-21		94
540	Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. **2013**, 19, 202-7		59
539	Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition. **2013**, 29, 659-61		3
538	Mitochondrial dynamics--mitochondrial fission and fusion in human diseases. **2013**, 369, 2236-51		629
537	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. **2013**, 19, 2213-31		57
536	Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. **2013**, 187, 78-89		51

535	Role of curcumin in idiopathic pulmonary arterial hypertension treatment: a new therapeutic possibility. **2013**, 81, 923-6		17
534	An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. **2013**, 19, 74-82		277
533	Pyrrolidine dithiocarbamate attenuates the development of monocrotaline-induced pulmonary arterial hypertension. **2013**, 209, 302-8		6
532	Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension. **2013**, 138, 409-17		21
531	Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. **2013**, 111, 1A-16A; quiz 17A-19A		48
530	Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. **2013**, 187, 648-57		117
529	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. *Vascular Pharmacology*, **2013**, 58, 211-8	5.9	16
528	Rho GTPases in pulmonary vascular dysfunction. *Vascular Pharmacology*, **2013**, 58, 202-10	5.9	11
527	Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats. **2013**, 169, 953-62		30
526	Nonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newborn. **2013**, 131, 79-87		51
525	Chronic obstructive pulmonary disease and cardiovascular diseases: a "vulnerable" relationship. **2013**, 187, 2-4		19
524	Are tyrosine kinase inhibitors the better serotonin inhibitors?. **2013**, 187, 4-5		3
523	Fetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia. **2013**, 74, 290-8		27
522	Combination of erythropoietin and sildenafil can effectively attenuate hypoxia-induced pulmonary hypertension in mice. **2013**, 3, 898-907		4
521	MicroRNA expression profile of pulmonary artery smooth muscle cells and the effect of let-7d in chronic thromboembolic pulmonary hypertension. **2013**, 3, 654-64		26
520	Evidence of synergistic/additive effects of sildenafil and erythropoietin in enhancing survival and migration of hypoxic endothelial cells. **2013**, 304, L230-9		15
519	Pathology and pathobiology of pulmonary hypertension. **2013**, 34, 551-9		79
518	Signal transduction in the development of pulmonary arterial hypertension. **2013**, 3, 278-93		61

517	The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies. **2013**, 3, 275-7	2
516	Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review. **2013**, 3, 499-506	20
515	PPAR□agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling. **2013**, 2013, 903947	17
514	The pulmonary hypertension academic research consortium. **2013**, 3, 203-5	3
513	The peroxisome proliferator-activated receptor □agonist GW0742 has direct protective effects on right heart hypertrophy. **2013**, 3, 926-35	18
512	Cellular microparticles in the pathogenesis of pulmonary hypertension. **2013**, 42, 272-9	43
511	Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. **2013**, 128, 1214-24	86
510	A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. **2013**, 288, 16557-16566	20
509	An investigation into beef calf mortality on five high-altitude ranches that selected sires with low pulmonary arterial pressures for over 20 years. **2013**, 25, 210-8	24
508	Involvement of serotonin mechanism in methamphetamine-induced chronic pulmonary toxicity in rats. **2013**, 32, 736-46	10
507	Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. **2013**, 41, 6005-17	44
506	Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. **2013**, 3, 20-30	57
505	Soluble JAGGED1 inhibits pulmonary hypertension by attenuating notch signaling. **2013**, 33, 2733-9	26
504	The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. **2013**, 98, 1274-8	9
503	C-terminus of ETA/ETB receptors regulate endothelin-1 signal transmission. **2013**, 19, 257-62	8
502	Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases. **2013**, 3, 1749-79	15
501	Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. **2013**, 5, 200ra117	168
500	Reactive oxygen species as therapeutic targets in pulmonary hypertension. **2013**, 7, 175-200	40

499	Cobalamin C defect presenting with isolated pulmonary hypertension. **2013**, 132, e248-51		24
498	Novel oral prostacyclin analog with thromboxane synthase inhibitory activity for management of pulmonary arterial hypertension. **2013**, 77, 1994-5		3
497	MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. **2013**, 19, 1-16		2
496	Biopterin metabolism and eNOS expression during hypoxic pulmonary hypertension in mice. **2013**, 8, e82594		17
495	Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?. **2014**, 21, 381-90		42
494	Pulmonary Arterial Hypertension and Insulin Resistance. **2014**, 2,		5
493	Molecular mechanisms of pulmonary arterial remodeling. **2014**, 20, 191-201		72
492	PKG-1 leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension. **2014**, 307, L537-44		14
491	Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis. **2014**, 64, 185-94		66
490	A report on the use of animal models and phenotyping methods in pulmonary hypertension research. **2014**, 4, 2-9		11
489	Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). **2014**, 4, 175-84		48
488	Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways. **2014**, 63, 309-15		24
487	The role of the osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the pathogenesis of pulmonary arterial hypertension. *Vascular Pharmacology*, **2014**, 63, 114-7	5.9	4
486	Novel non-surgical prenatal approaches to treating congenital diaphragmatic hernia. **2014**, 19, 349-56		13
485	Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. **2014**, 94, 148-56		47
484	Infections in the immunosuppressed host. **2014**, 11 Suppl 4, S211-20		16
483	Take a deep breath: understanding pulmonary arterial hypertension. **2014**, 37, 188-98		
482	Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat. **2014**, 4, 462-70		15

481	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. **2014**, 172, 332-9	34
480	Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. **2014**, 31, 1553-65	59
479	Cellular interplay in pulmonary arterial hypertension: implications for new therapies. **2014**, 1843, 885-93	21
478	Leukotrienes in pulmonary arterial hypertension. **2014**, 58, 387-93	29
477	Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. **2014**, 211, 314-33	12
476	Thrombosis, platelets, microparticles and PAH: more than a clot. **2014**, 19, 1230-5	33
475	The Right Heart. **2014**,	1
474	Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. **2014**, 33, 12-9	29
473	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. **2014**, 20, 1289-300	183
472	Metabolomics reveals metabolite changes in acute pulmonary embolism. **2014**, 13, 805-16	29
471	Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. **2014**, 64, 1248-59	107
470	Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. **2014**, 740, 379-87	41
469	Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. **2014**, 306, H1314-23	63
468	The impact of metabolic syndrome, recently diagnosed diabetes and hypertension on right ventricular remodeling. Is there difference between risk factors?. **2014**, 36, 295-301	9
467	Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. **2014**, 54, 137-48	34
466	The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. **2014**, 1, 18-39	21
465	Involvement of calcium-sensing receptors in hypoxia-induced vascular remodeling and pulmonary hypertension by promoting phenotypic modulation of small pulmonary arteries. **2014**, 396, 87-98	24
464	Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. **2014**, 51, 155-62	45

463	Rho GTPases in the regulation of pulmonary vascular barrier function. **2014**, 355, 675-85	35
462	Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. **2014**, 14, 368-78	19
461	Endothelial progenitor cells and pulmonary arterial hypertension. **2014**, 23, 595-601	20
460	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. **2014**, 173, 154-62	28
459	Novel and emerging therapies for pulmonary hypertension. **2014**, 189, 394-400	62
458	MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. **2014**, 114, 67-78	138
457	Naringenin adds to the protective effect of L-arginine in monocrotaline-induced pulmonary hypertension in rats: favorable modulation of oxidative stress, inflammation and nitric oxide. **2014**, 62, 161-70	29
456	Persistent pulmonary arterial hypertension in the newborn (PPHN): a frequent manifestation of TMEM70 defective patients. **2014**, 111, 353-359	28
455	New molecular genetic tests in the diagnosis of heart disease. **2014**, 34, 137-56, vii-viii	6
454	Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension. **2015**, 148, 655-666	22
453	Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway. **2015**, 5, 656-60	16
452	An improved method for detecting circulating microRNAs with S-Poly(T) Plus real-time PCR. **2015**, 5, 15100	60
451	Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. **2015**, 7, 695-713	96
450	BMPR2 spruces up the endothelium in pulmonary hypertension. **2015**, 6, 703-8	4
449	Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. **2015**, 112, E2677-86	117
448	Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. **2015**, 211, 118-33	30
447	Pyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1□**2015**, 308, H951-9	17
446	Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. **2015**, 24, 566-72	20

445	Prognostic factors in pediatric pulmonary arterial hypertension: A systematic review and meta-analysis. **2015**, 184, 198-207		73
444	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. **2015**, 192, 342-55		16
443	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. **2015**, 101, 1792-9		64
442	Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension. **2015**, 30, 66-79		14
441	Chronic cardiovascular disease-associated gene network analysis in human umbilical vein endothelial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. **2015**, 15, 157-71		9
440	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. **2015**, 172, 1397-414		21
439	The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. **2015**, 290, 2069-85		67
438	Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. **2015**, 12, 269-73		8
437	Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats. **2015**, 180, 134-41		47
436	Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway. **2015**, 82, 153-66		63
435	Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension. **2015**, 117, 525-35		106
434	To be EndMT or not to be, that is the question in pulmonary hypertension. **2015**, 6, 547-50		11
433	Asymmetric dimethyl arginine induces pulmonary vascular dysfunction via activation of signal transducer and activator of transcription 3 and stabilization of hypoxia-inducible factor 1-alpha. *Vascular Pharmacology*, **2015**, 73, 138-48	5.9	20
432	Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. **2015**, 5, 12098		42
431	MicroRNA-27b plays a role in pulmonary arterial hypertension by modulating peroxisome proliferator-activated receptor □dependent Hsp90-eNOS signaling and nitric oxide production. **2015**, 460, 469-75		30
430	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. **2015**, 46, 1084-94		29
429	Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. **2015**, 15, 195-203		46
428	Endothelial uncoupling protein 2 regulates mitophagy and pulmonary hypertension during intermittent hypoxia. **2015**, 35, 1166-78		76

427	Loss of microRNA-17~92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. **2015**, 191, 678-92	56
426	Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. **2015**, 172, 2219-31	62
425	MicroRNA-145-targeted drug and its preventive effect on pulmonary arterial hypertension (patent WO2012153135 A1). **2015**, 25, 723-7	6
424	Discordant Regulation of microRNA Between Multiple Experimental Models and Human Pulmonary Hypertension. **2015**, 148, 481-490	27
423	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. **2015**, 524, 356-60	85
422	Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension. **2015**, 41, 435-43	14
421	Thrombolysis in Pulmonary Embolism. **2015**,	3
420	Withania somnifera shows a protective effect in monocrotaline-induced pulmonary hypertension. **2015**, 53, 147-57	14
419	MiR-328 targeting PIM-1 inhibits proliferation and migration of pulmonary arterial smooth muscle cells in PDGFBB signaling pathway. **2016**, 7, 54998-55011	30
418	Sex and Gender Differences in Cardiovascular Disease. **2016**, 61-87	7
417	D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension. **2016**, 6, 211-8	15
416	The Association between ESR and CRP and Systemic Hypertension in Sarcoidosis. **2016**, 2016, 2402515	6
415	Knockdown of AMPK2 Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation via mTOR/Skp2/p27(Kip1) Signaling Pathway. **2016**, 17,	11
414	Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension. **2016**, 11, e0147827	20
413	Calcium-Sensing Receptor Regulates Cytosolic [Ca] and Plays a Major Role in the Development of Pulmonary Hypertension. **2016**, 7, 517	39
412	Distinct right ventricle remodeling in response to pressure overload in the rat. **2016**, 311, H85-95	24
411	Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol. **2016**, 5, 89	7
410	Pulmonary Hypertension and Inflammation/Infection. **2016**, 55, 1409-10	

409	Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human Diseases. **2016**, 50, 595-618	49
408	Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. **2016**, 8, 74-82	11
407	miR-17/20 Controls Prolyl Hydroxylase 2 (PHD2)/Hypoxia-Inducible Factor 1 (HIF1) to Regulate Pulmonary Artery Smooth Muscle Cell Proliferation. **2016**, 5,	28
406	Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. **2016**, 38, 1228-1236.e1	18
405	Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells. **2016**, 159, 116-120	6
404	Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1. **2016**, 148, 1-8	16
403	HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension. **2016**, 194, 866-877	68
402	miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?. **2016**, 8, 1311-1313	2
401	Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension. **2016**, 36, 2078-87	83
400	Nitro-Oleic Acid Prevents Hypoxia- and Asymmetric Dimethylarginine-Induced Pulmonary Endothelial Dysfunction. **2016**, 30, 579-586	10
399	Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension - Insights From the IBUKI and AIR Studies. **2016**, 80, 835-42	18
398	Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food. **2016**, 6, S66-74	10
397	The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1. **2016**, 6, 82-92	28
396	An international physician survey of pulmonary arterial hypertension management. **2016**, 6, 338-46	9
395	Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. **2016**, 173, 2859-79	35
394	Smooth Muscle Insulin-Like Growth Factor-1 Mediates Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice. **2016**, 55, 779-791	22
393	Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. **2016**, 6, 369-80	24
392	Automated Measurement of Blood Vessels in Tissues from Microscopy Images. **2016**, 78, 12.44.1-12.44.13	3

391	MURC deficiency in smooth muscle attenuates pulmonary hypertension. *Nature Communications*, **2016**, 7, 12417	17.4	15
390	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. **2016**, 114, 103-109		25
389	cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during Fuzi and Beimu Combination Treatment of Experimental Pulmonary Hypertension. **2016**, 6, 34903		15
388	The Impact of White-Coat Hypertension on Cardiac Mechanics. **2016**, 18, 617-22		14
387	Transforming growth factor-beta1 upregulation triggers pulmonary artery smooth muscle cell proliferation and apoptosis imbalance in rats with hypoxic pulmonary hypertension via the PTEN/AKT pathways. **2016**, 77, 141-154		35
386	TGF-1/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblasts. **2016**, 15, 2		12
385	Lung Circulation. **2016**, 6, 897-943		49
384	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. **2016**, 12, 63-8		13
383	Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. **2016**, 4, 281-90		17
382	Egr-1 identifies neointimal remodeling and relates to progression in human pulmonary arterial hypertension. **2016**, 35, 481-90		17
381	Nestin-expressing vascular wall cells drive development of pulmonary hypertension. **2016**, 47, 876-88		24
380	A study on the involvement of GABA-transaminase in MCT induced pulmonary hypertension. **2016**, 36, 10-21		3
379	Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension. **2016**, 54, 461-8		61
378	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. **2017**, 151, 468-480		57
377	Exosomes Derived from Human Pulmonary Artery Endothelial Cells Shift the Balance between Proliferation and Apoptosis of Smooth Muscle Cells. **2017**, 137, 43-53		50
376	Therapeutic and pathological roles of fibroblast growth factors in pulmonary diseases. **2017**, 246, 235-244		16
375	Analysis of hypoxia-induced noncoding RNAs reveals metastasis-associated lung adenocarcinoma transcript 1 as an important regulator of vascular smooth muscle cell proliferation. **2017**, 242, 487-496		41
374	Interleukin-6 -572C/G polymorphism is associated with serum interleukin-6 levels and risk of idiopathic pulmonary arterial hypertension. **2017**, 11, 171-177		16

373	Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. **2017**, 14, 830-841	16
372	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. **2017**, 76, 422-426	76
371	Bone marrow-derived mesenchymal stem cells modified with IGFBP-3 inhibit the proliferation of pulmonary artery smooth muscle cells. **2017**, 39, 223-230	11
370	Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension. **2017**, 112, 30	15
369	Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. **2017**, 16, 743-751	11
368	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. **2017**, 128, 50-56	25
367	Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model. **2017**, 25, 206-211	9
366	Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension. **2017**, 37, 1513-1523	54
365	Pinocembrin ex vivo preconditioning improves the therapeutic efficacy of endothelial progenitor cells in monocrotaline-induced pulmonary hypertension in rats. **2017**, 138, 193-204	10
364	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. **2017**, 5, 717-726	62
363	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. **2017**, 129, 124-129	9
362	Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension. **2017**, 6, 477-485	6
361	Critical effects of epigenetic regulation in pulmonary arterial hypertension. **2017**, 74, 3789-3808	10
360	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. **2017**, 7, 505-513	14
359	Advances in treatment of pulmonary arterial hypertension: patent review. **2017**, 27, 907-918	9
358	Pulmonary vascular remodeling in pulmonary hypertension. **2017**, 367, 643-649	112
357	A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries. **2017**, 795, 75-83	11
356	Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. **2017**, 102, 180-189	14

355	Calcium signalling induced by in vitro exposure to silicium dioxide nanoparticles in rat pulmonary artery smooth muscle cells. **2017**, 375, 37-47	16
354	The Nitric Oxide Pathway in Pulmonary Vascular Disease. **2017**, 120, S71-S79	54
353	Pathology and Pathobiology of Pulmonary Hypertension. **2017**, 38, 571-584	26
352	Therapeutic application of apoptosis signal-regulating kinase 1 inhibitors. **2017**, 66, 85-90	18
351	miR-200c regulates endothelin-1 induced PASMCs abnormal proliferation and apoptosis. **2017**, 69, 877-886	6
350	Diethylcarbamazine: A potential treatment drug for pulmonary hypertension?. **2017**, 333, 92-99	2
349	Prostaglandin E1 Attenuates Pulmonary Artery Remodeling by Activating Phosphorylation of CREB and the PTEN Signaling Pathway. **2017**, 7, 9974	2
348	Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. **2017**, 83, 2778-2788	10
347	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. **2017**, 7, 741-746	10
346	Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. **2017**, 44, 377-385	79
345	Right Atrial Deformation in Predicting Outcomes in Pediatric Pulmonary Hypertension. **2017**, 10,	28
344	miR-4632 mediates PDGF-BB-induced proliferation and antiapoptosis of human pulmonary artery smooth muscle cells via targeting cJUN. **2017**, 313, C380-C391	25
343	3D-Zellkultursystem f□ die Nachbildung biologischer Barrieren. **2017**, 23, 422-423	
342	Arrhythmias in pulmonary arterial hypertension. **2017**, 1,	6
341	Activation of GPER ameliorates experimental pulmonary hypertension in male rats. **2017**, 97, 208-217	20
340	Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. **2017**, 195, 425-437	81
339	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. **2017**, 195, 583-595	95
338	Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. **2017**, 113, 276-287	11

337	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. **2017**, 8, 858	18
336	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. **2017**, 8, 707	29
335	Hemodynamic and Pathologic Characterization of the TASK-1 Mouse Does Not Demonstrate Pulmonary Hypertension. **2017**, 4, 177	14
334	Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. **2017**, 8, 220	39
333	Intersectin-1s deficiency in pulmonary pathogenesis. **2017**, 18, 168	3
332	Mechanisms of N-acetylcysteine in reducing monocrotaline-induced pulmonary hypertension in rats: Inhibiting the expression of Nox1 in pulmonary vascular smooth muscle cells. **2017**, 16, 6148-6155	3
331	Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients. **2018**, 37, 1547-1553	2
330	Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension. **2018**, 198, 788-802	60
329	Global Proteomics Deciphered Novel-Function of Osthole Against Pulmonary Arterial Hypertension. **2018**, 8, 5556	18
328	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. **2018**, 137, 2371-2389	46
327	Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. **2018**, 48, 874-884	22
326	Right heart remodeling induced by arterial hypertension: Could strain assessment be helpful?. **2018**, 20, 400-407	12
325	Upregulation of Klotho potentially inhibits pulmonary vascular remodeling by blocking the activation of the Wnt signaling pathway in rats with PM2.5-induced pulmonary arterial hypertension. **2018**, 119, 5581-5597	8
324	FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. **2018**, 96, 223-235	45
323	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. **2018**, 18, 41	31
322	Genistein rescues hypoxia-induced pulmonary arterial hypertension through estrogen receptor and adrenoceptor signaling. **2018**, 58, 110-118	11
321	Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research. **2018**, 122, 1021-1032	89
320	Impact of the Right Ventricular Sokolow-Lyon Index in Children with Idiopathic Pulmonary Arterial Hypertension. **2018**, 39, 1115-1122	3

319	Acute diffuse alveolar haemorrhage accompanied by gastrointestinal bleeding in a patient with serious systemic lupus erythematosus: A case report. **2018**, 46, 2046-2053		1
318	Pulmonary arterial stiffness indices assessed by intravascular ultrasound in children with early pulmonary vascular disease: prediction of advanced disease and mortality during 20-year follow-up. **2018**, 19, 216-224		13
317	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. **2018**, 197, 373-385		57
316	Prostanoid EP agonist L-902,688 activates PPAR and attenuates pulmonary arterial hypertension. **2018**, 314, L349-L359		14
315	Tetrahydrobiopterin (BH): Targeting endothelial nitric oxide synthase as a potential therapy for pulmonary hypertension. **2018**, 36, e12312		6
314	Adenosine A(2A) receptor activation reverses hypoxia-induced rat pulmonary artery smooth muscle cell proliferation via cyclic AMP-mediated inhibition of the SDF1-CXC4 signaling pathway. **2018**, 42, 607-614		1
313	Drug abuse and HIV-related pulmonary hypertension: double hit injury. **2018**, 32, 2651-2667		7
312	Human Mesenchymal Stem Cell Therapy Reverses Su5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice. **2018**, 9, 1395		17
311	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. **2018**, 11, e007653		5
310	The expanding role of implantable devices to monitor heart failure and pulmonary hypertension. *Nature Reviews Cardiology*, **2018**, 15, 770-779	14.8	11
309	3-Deoxy-3-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. **2018**, 11, e007402		10
308	cGMP interacts with tropomyosin and downregulates actin-tropomyosin-myosin complex interaction. **2018**, 19, 201		0
307	PDGFBB promotes proliferation and migration via regulating miR-1181/STAT3 axis in human pulmonary arterial smooth muscle cells. **2018**, 315, L965-L976		16
306	Cardioprotection Induced by Activation of GPER in Ovariectomized Rats With Pulmonary Hypertension. **2018**, 73, 1158-1166		10
305	Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome. **2018**, 8, 9681		29
304	Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline. **2018**, 19, 94		16
303	Ceramide is a Potential Activator of Immune Responses Against Tumors. **2018**, 155, 579-580		3
302	rhACE2 Therapy Modifies Bleomycin-Induced Pulmonary Hypertension via Rescue of Vascular Remodeling. **2018**, 9, 271		22

301	Extracellular retention of PDGF-B directs vascular remodeling in mouse hypoxia-induced pulmonary hypertension. **2018**, 314, L593-L605	4
300	Is the fibroblast growth factor signaling pathway a victim of receptor tyrosine kinase inhibition in pulmonary parenchymal and vascular remodeling?. **2018**, 315, L248-L252	8
299	Beneficial Effect of (Linn) against Monocrotaline-Induced Pulmonary Hypertension in Rats. **2018**, 5,	7
298	Platelet activation markers in children with congenital heart disease associated with pulmonary arterial hypertension. **2018**, 13, 506-511	12
297	Interventions and mechanisms of N-acetylcysteine on monocrotaline-induced pulmonary arterial hypertension. **2018**, 15, 5503-5509	2
296	Reply. **2018**, 155, 578-579	
295	Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension. **2018**, 48, 839-853	4
294	Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension. **2018**, 51, 119-129	16
293	Inhalation of repurposed drugs to treat pulmonary hypertension. **2018**, 133, 34-44	11
292	Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. **2019**, 597, 1103-1119	19
291	Norepinephrine stimulation downregulates the □adrenergic receptor-nitric oxide pathway in human pulmonary artery endothelial cells. **2019**, 234, 1842-1850	2
290	Role of integrin-linked kinase in the hypoxia-induced phenotypic transition of pulmonary artery smooth muscle cells: Implications for hypoxic pulmonary hypertension. **2019**, 382, 111476	4
289	Attenuating Pulmonary Hypertension by Protecting the Integrity of Glycocalyx in Rats Model of Pulmonary Artery Hypertension. **2019**, 42, 1951-1956	7
288	Intrauterine Growth Restriction Programs Intergenerational Transmission of Pulmonary Arterial Hypertension and Endothelial Dysfunction via Sperm Epigenetic Modifications. **2019**, 74, 1160-1171	13
287	Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor. **2019**, 865, 172777	7
286	Systematic Elucidation of the Mechanism of Genistein against Pulmonary Hypertension via Network Pharmacology Approach. **2019**, 20,	17
285	Crop Production Pushes Up Greenhouse Gases Emissions in China: Evidence from Carbon Footprint Analysis based on National Statistics Data. **2019**, 11, 4931	5
284	Practical management of riociguat in patients with pulmonary arterial hypertension. **2019**, 13, 1753466619868938	4

283	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. **2019**, 200, 1550-1554		2
282	Current new challenges in the management of ulcerative colitis. **2019**, 17, 36-44		22
281	Circular RNA hsa_circ_0016070 Is Associated with Pulmonary Arterial Hypertension by Promoting PASMC Proliferation. **2019**, 18, 275-284		36
280	MicroRNA-30a-5p promotes proliferation and inhibits apoptosis of human pulmonary artery endothelial cells under hypoxia by targeting YKL-40. **2019**, 20, 236-244		12
279	Oxidation of PKGI mediates an endogenous adaptation to pulmonary hypertension. **2019**, 116, 13016-13025		8
278	Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling. **2019**, 20, 121		9
277	Right ventricular dysfunction in arterial hypertension: still terra incognita?. **2019**, 33, 491-498		1
276	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 2204	17.4	39
275	Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. **2019**, 172, 302-310		2
274	A RASSF1A-HIF1 loop drives Warburg effect in cancer and pulmonary hypertension. *Nature Communications*, **2019**, 10, 2130	17.4	34
273	Ventricular interdependence in hypertension: fact or fiction?. **2019**, 33, 489-490		
272	Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. **2019**, 9, 2045894019848644		5
271	Pharmacological inhibition of catenin prevents EndMT in vitro and vascular remodeling in vivo resulting from endothelial Akt1 suppression. **2019**, 164, 205-215		17
270	The multifaceted roles of FOXM1 in pulmonary disease. **2019**, 17, 35		16
269	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. **2019**, 62, 4979-4990		13
268	Altered proteasome function in right ventricular hypertrophy. **2020**, 116, 406-415		5
267	Cathepsin S promotes the development of pulmonary arterial hypertension. **2019**, 317, L1-L13		13
266	Activation of K 7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation. **2019**, 176, 2131-2145		11

265	Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review. **2019**, 10, 75		8
264	Exploration of the Notch3-HES5 signal pathway in monocrotaline-induced pulmonary hypertension using rat model. **2019**, 14, 396-402		3
263	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. **2019**, 10, 54		3
262	Long non-coding RNA CASC2 suppresses pulmonary artery smooth muscle cell proliferation and phenotypic switch in hypoxia-induced pulmonary hypertension. **2019**, 20, 53		21
261	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. **2019**, 53,		21
260	Notch3 signaling activation in smooth muscle cells promotes extrauterine growth restriction-induced pulmonary hypertension. **2019**, 29, 639-651		13
259	Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-[(Transforming Growth Factor-]-Dependent Pulmonary Arterial Hypertension. **2019**, 39, 1191-1202		20
258	Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension. **2019**, 850, 126-134		8
257	Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-signaling. **2019**, 234, 17482-17493		17
256	Formononetin attenuates monocrotaline-induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats. **2019**, 20, 4984-4992		9
255	A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 5183	17.4	12
254	Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH. **2019**, 9, 19832		6
253	Pulmonary Circulation in Obesity, Diabetes, and Metabolic Syndrome. **2019**, 10, 297-316		3
252	The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. **2019**, 8, e014201		16
251	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. **2019**, 199, 1407-1420		25
250	Aqp-1 Gene Knockout Attenuates Hypoxic Pulmonary Hypertension of Mice. **2019**, 39, 48-62		19
249	SphK1/S1P mediates TGF-1-induced proliferation of pulmonary artery smooth muscle cells and its potential mechanisms. **2019**, 9, 2045894018816977		13
248	CLIC4/Arf6 Pathway. **2019**, 124, 52-65		12

247	Value of lung perfusion scintigraphy in patients with idiopathic pulmonary arterial hypertension: a patchy pattern to consider. **2019**, 9, 2045894018816968		5
246	Twik-2 mouse demonstrates pulmonary vascular heterogeneity in intracellular pathways for vasocontractility. **2019**, 7, e13950		6
245	Long noncoding RNA UCA1 promotes the proliferation of hypoxic human pulmonary artery smooth muscle cells. **2019**, 471, 347-355		24
244	Long noncoding RNA Hoxaas3 contributes to hypoxia-induced pulmonary artery smooth muscle cell proliferation. **2019**, 115, 647-657		32
243	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. **2019**, 2045894019837849		1
242	Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy. **2020**, 16, 113-119		2
241	Unique wreath-like smooth muscle proliferation of the pulmonary vasculature in pulmonary veno-occlusive disease versus pulmonary arterial hypertension. **2020**, 119, 300-309		3
240	Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. *Nature Reviews Cardiology*, **2020**, 17, 96-115	14.8	63
239	Retrospective Validation of the REVEAL 2.0´Risk Score With the Australian and New´Zealand Pulmonary Hypertension Registry Cohort. **2020**, 157, 162-172		17
238	Synthetic routes to treprostinil N-acyl methylsulfonamide. **2020**, 61, 151428		1
237	Pulmonary hypertension: Pathophysiology beyond the lung. **2020**, 151, 104518		13
236	Involvement of miR-200b-PKC□signalling in pulmonary hypertension in cor pulmonale model. **2020**, 47, 478-484		
235	Linking lncRNAs to regulation, pathogenesis, and diagnosis of pulmonary hypertension. **2019**, 1-15		3
234	Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments. **2020**, 7, 100771		0
233	Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP. **2020**, 242, 117159		2
232	The cGMP system: components and function. **2020**, 401, 447-469		18
231	Pathological Mechanisms and Potential Therapeutic Targets of Pulmonary Arterial Hypertension: A Review. **2020**, 11, 1623-1639		9
230	IRAG1 Deficient Mice Develop PKG1□Dependent Pulmonary Hypertension. **2020**, 9,		2

229	Integrative analysis reveals key mRNA and long non-coding RNA interaction in idiopathic pulmonary arterial hypertension. **2020**,	
228	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. **2020**, 10, 2045894020947283	2
227	Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension. **2020**, 887, 173438	4
226	Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma. **2020**, 191, 113634	1
225	Genetic knockout and pharmacologic inhibition of NCX1 attenuate hypoxia-induced pulmonary arterial hypertension. **2020**, 529, 793-798	1
224	Increased levels of platelet-derived microparticles in pulmonary hypertension. **2020**, 195, 120-124	5
223	Vascular Metabolic Mechanisms of Pulmonary Hypertension. **2020**, 40, 444-454	2
222	BK Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats. **2021**, 35, 719-732	2
221	Icariin Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension via the Inhibition of TGF-1/Smads Pathway in Rats. **2020**, 2020, 9238428	4
220	Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. **2020**, 190, 113496	3
219	Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). **2020**, 10, 2045894020942121	0
218	In situ Evidence of Collagen V and Interleukin-6/Interleukin-17 Activation in Vascular Remodeling of Experimental Pulmonary Hypertension. **2020**, 87, 356-366	2
217	FGF12 (Fibroblast Growth Factor 12) Inhibits Vascular Smooth Muscle Cell Remodeling in Pulmonary Arterial Hypertension. **2020**, 76, 1778-1786	10
216	TIGAR reduces smooth muscle cell autophagy to prevent pulmonary hypertension. **2020**, 319, H1087-H1096	6
215	Heart Rate Reduction by Ivabradine: Slowly but Surely?. **2020**, 63, 725-726	
214	Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives. **2020**, 63, 15153-15186	5
213	Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies. **2020**, 10, 2045894020963836	2
212	Effect of p53 activation on experimental right ventricular hypertrophy. **2020**, 15, e0234872	2

211	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. **2020**, 21, 136	4
210	Electrophilic nitrated fatty acids are potential therapeutic candidates for inflammatory and fibrotic lung diseases. **2020**, 102, 28-38	3
209	is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. **2020**, 56,	1
208	Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More. **2020**, 43, 366-374	12
207	Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. **2020**, 75, 935-945	10
206	NADPH oxidase-mediated endothelial injury in HIV- and opioid-induced pulmonary arterial hypertension. **2020**, 318, L1097-L1108	7
205	Remodeling Matrix Synthesis in a Rat Model of Aortocaval Fistula and the Cyclic Stretch: Impaction in Pulmonary Arterial Hypertension-Congenital Heart Disease. **2020**, 21,	1
204	Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension. **2020**,	1
203	Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension. **2020**, 11, 145	8
202	Novel angiogenesis strategy to ameliorate pulmonary hypertension. **2021**, 161, e417-e434	4
201	Pulmonary artery denervation for pulmonary arterial hypertension. **2021**, 31, 252-260	9
200	hsa_circNFXL1_009 modulates apoptosis, proliferation, migration, and potassium channel activation in pulmonary hypertension. **2021**, 23, 1007-1019	8
199	Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. **2021**, 64, 100-114	10
198	Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. **2021**, 35, 235-259	7
197	Riociguat: Clinical research and evolving role in therapy. **2021**, 87, 2645-2662	7
196	Activation of yes-associated protein mediates sphingosine-1-phosphate-induced proliferation and migration of pulmonary artery smooth muscle cells and its potential mechanisms. **2021**, 236, 4694-4708	2
195	miR-150-PTPMT1-cardiolipin signaling in pulmonary arterial hypertension. **2021**, 23, 142-153	3
194	Keratin 1 attenuates hypoxic pulmonary artery hypertension by suppressing pulmonary artery media smooth muscle expansion. **2021**, 231, e13558	6

193	The role of chemokines and chemokine receptors in pulmonary arterial hypertension. **2021**, 178, 72-89	23
192	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. **2021**, 178, 31-53	5
191	General discussion, conclusion remark, and future direction. **2021**, 135-144	
190	Genetic Delivery and Gene Therapy in Pulmonary Hypertension. **2021**, 22,	3
189	Role of Medicinal Plants in Pulmonary Hypertension. **2021**, 303-316	0
188	Experimental Models. **2021**, 27-52	
187	Endothelial progenitor cells in pulmonary diseases, repair and regeneration. **2021**, 119-134	
186	Potential Cellular Targets Associated with the Signaling of the Pulmonary Hypertension. **2021**, 435-445	
185	Medicinal Plants Used in the Treatment of Pulmonary Hypertension. **2021**, 317-339	
184	Potential Complications With Cryopreserved Cadaveric Veins in Arteriovenous Loop Formation for Head and Neck Microvascular Reconstruction. **2021**, 32, 1874-1876	1
183	Encyclopedia of Molecular Pharmacology. **2021**, 1-8	
182	Identification of biomarkers and pathways for the SARS-CoV-2 infections that make complexities in pulmonary arterial hypertension patients. **2021**, 22, 1451-1465	19
181	Downregulation of Soluble Guanylate Cyclase and Protein Kinase G With Upregulated ROCK2 in the Pulmonary Artery Leads to Thromboxane A2 Sensitization in Monocrotaline-Induced Pulmonary Hypertensive Rats. **2021**, 12, 624967	1
180	Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension. **2021**, 22,	1
179	Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension. **2021**, 118,	5
178	Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension. **2021**, 22,	2
177	Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension. **2021**, 10,	6
176	Circular RNA-HIPK3 regulates human pulmonary artery endothelial cells function and vessel growth by regulating microRNA-328-3p/STAT3 axis. **2021**, 11, 20458940211000234	5

175	Endothelial Dysfunction and Disruption in Pulmonary Hypertension.	1
174	Biological drug and drug delivery-mediated immunotherapy. **2021**, 11, 941-960	26
173	Activation of AMPK inhibits Galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP. **2021**, 476, 3037-3049	2
172	Glutaminolysis: A Driver of Vascular and Cardiac Remodeling in Pulmonary Arterial Hypertension. **2021**, 8, 667446	4
171	Immunometabolic Endothelial Phenotypes: Integrating Inflammation and Glucose Metabolism. **2021**, 129, 9-29	7
170	Influence of atorvastatin on metabolic pattern of rats with pulmonary hypertension. **2021**, 13, 11954-11968	3
169	Inhibition of Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinase 2 (MK2) is Protective in Pulmonary Hypertension. **2021**, 77, 1248-1259	1
168	Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling. **2021**, 77, 1787-1798	1
167	Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension. **2021**, 9,	2
166	Bioinformatic analysis and validation of microRNA-508-3p as a protective predictor by targeting NR4A3/MEK axis in pulmonary arterial hypertension. **2021**, 25, 5202-5219	2
165	Role of Krüppel-like factors in pulmonary arterial hypertension. **2021**, 134, 105977	1
164	High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19.	1
163	ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension. **2021**, 10,	6
162	Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. **2021**, 320, L1025-L1037	1
161	Role of pulmonary arterial capacitance in predicting mortality in patients with pulmonary hypertension: A systematic review and meta-analysis. **2021**, 333, 202-209	0
160	The mA methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension. **2021**, 274, 119366	10
159	Erectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease. **2021**, 10,	2
158	Lung Pericytes in Pulmonary Vascular Physiology and Pathophysiology. **2021**, 11, 2227-2247	4

157	A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. **2021**, 15, 2947-2959		0
156	Prognostic biomarkers in pediatric pulmonary arterial hypertension. **2021**, 11, 1089-1101		
155	Evidence for Multiple Origins of De Novo Formed Vascular Smooth Muscle Cells in Pulmonary Hypertension: Challenging the Dominant Model of Pre-Existing Smooth Muscle Expansion. **2021**, 18,		
154	Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension-a registry-based analysis. **2021**, 11, 1037-1047		2
153	Targeting JP2: A New Treatment for Pulmonary Hypertension. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 2003446	6.7	1
152	Sex Differences, Estrogen Metabolism and Signaling in the Development of Pulmonary Arterial Hypertension. **2021**, 8, 719058		3
151	Ubiquinol ameliorates endothelial dysfunction and increases expression of miRNA-34a in a rat model of pulmonary hypertension. **2021**, 7, 23-31		1
150	Autoimmunity in Pulmonary Arterial Hypertension: Evidence for Local Immunoglobulin Production. **2021**, 8, 680109		0
149	Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. **2021**, 27, 786.e1-786.e8		1
148	Complement-containing small extracellular vesicles from adventitial fibroblasts induce proinflammatory and metabolic reprogramming in macrophages. **2021**, 6,		1
147	Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension. **2021**, 11, 20458940211041500		0
146	Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension. **2021**, 12, 712583		1
145	Pulmonary Hypertension in Obese Mice Is Accompanied by a Reduction in PPAR-□Expression in Pulmonary Artery. **2021**, 12, 701994		
144	Potassium (K) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation. **2021**, 225, 107835		8
143	Mouse model of experimental pulmonary hypertension: Lung angiogram and right heart catheterization. **2021**, 11, 20458940211041512		2
142	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. **2021**, 11, 20458940211052823		1
141	Novel molecular insights and public omics data in pulmonary hypertension. **2021**, 1867, 166200		2
140	Disrupted PI3K subunit p110□signaling protects against pulmonary hypertension and reverses established disease in rodents. **2021**, 131,		2

139	Low-intensity pulsed ultrasound prevents angiotensin II-induced aortic smooth muscle cell phenotypic switch via hampering miR-17-5p and enhancing PPAR-**2021**, 911, 174509	0
138	Lumican deficiency promotes pulmonary arterial remodeling. **2021**, 237, 63-81	0
137	Role of IL-33 receptor (ST2) deletion in diaphragm contractile and mitochondrial function in the Sugen5416/hypoxia model of pulmonary hypertension. **2022**, 295, 103783	0
136	Epigenetic mechanisms underlying the benefits of flavonoids in cardiovascular health and diseases: are long non-coding RNAs rising stars?. **2021**, 1-19	4
135	S1P induces proliferation of pulmonary artery smooth muscle cells by promoting YAP-induced Notch3 expression and activation. **2021**, 296, 100599	2
134	Circulating nerve growth factor receptor positive cells are associated with severity and prognosis of pulmonary arterial hypertension. **2021**, 11, 2045894021990525	1
133	Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS. **2021**, 59, 1133-1138	
132	Smooth Muscle Cell Ion Channels in Pulmonary Arterial Hypertension: Pathogenic Role in Pulmonary Vasoconstriction and Vascular Remodeling. **2016**, 295-324	1
131	Mitochondrial and Metabolic Drivers of Pulmonary Vascular Endothelial Dysfunction in Pulmonary Hypertension. **2017**, 967, 373-383	26
130	Caveolin-1 Regulation of Endothelial Nitric Oxide Synthase (eNOS) Function and Oxidative Stress in the Endothelium. **2014**, 1343-1363	6
129	Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. **2018**, 3,	25
128	The multifaceted role of ischemia/reperfusion in sickle cell anemia. **2020**, 130, 1062-1072	24
127	Endoplasmic reticulum stress and pulmonary hypertension. **2020**, 10, 2045894019900121	5
126	Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. **2014**, 9, e109291	20
125	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. **2018**, 13, e0195047	7
124	The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats. **2020**, 15, e0240692	2
123	A retrospective study on children with pulmonary arterial hypertension: A single-center experience. **2018**, 20, 41-47	7
122	MicroRNA-483 amelioration of experimental pulmonary hypertension. **2020**, 12, e11303	13

121	Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. **2018**, 13, 35-37	9
120	TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway. **2019**, 11, 4050-4065	13
119	Chronic obstructive sleep apnea accelerates pulmonary remodeling via TGF-/miR-185/CoLA1 signaling in a canine model. **2016**, 7, 57545-57555	13
118	5-HT induces PPAR reduction and proliferation of pulmonary artery smooth muscle cells via modulating GSK-3/catenin pathway. **2017**, 8, 72910-72920	5
117	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. **2020**, 27, 7168-7188	10
116	plays a role in the high-altitude adaptation of Tibetans. **2017**, 38, 155-162	9
115	MicroRNA-15a-5p induces pulmonary artery smooth muscle cell apoptosis in a pulmonary arterial hypertension model via the VEGF/p38/MMP-2 signaling pathway. **2020**, 45, 461-474	8
114	Hypoxia-inducible factors- as a regulator for forkhead box protein M1 in pulmonary artery hypertension. **2019**, 18, 59	2
113	An Overview of miRNAs Involved in PASMC Phenotypic Switching in Pulmonary Hypertension. **2021**, 2021, 5765029	1
112	Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension. **2021**, 18,	0
111	Etiology and prevalence of pulmonary arterial hypertension. **2013**, 6-22	
110	Experimental Models. **2014**, 45-67	
109	Pathophysiology and Treatment of Pulmonary Arterial Hypertension. **2015**, 949-974	
108	Mechanisms of Thrombosis. **2015**, 1-17	3
107	<i>In Vitro</i> Characterisation of Pharmacological Effect of Prostacyclin Analogues in Comparison to Phosphodiesterase Inhibitors on Small Human Pulmonary Vessels. **2017**, 07, 131-142	0
106	Successful Liver Transplant Complicated by Severe Portopulmonary Hypertension After an Initial Aborted Attempt: Case Report and Review of Treatment Options. **2017**, 15, 361-365	
105	Intracardiac hemodynamic abnormalities in patients with sarcoidosis. **2018**, 28, 567-575	
104	Combined use of arginase II and tadalafil inhibitors for the correction of monocrotaline pulmonary hypertension. **2019**, 5, 79-85	2

103	Limitations and Flaws of Preclinical Pulmonary Hypertension Studies. **2020**, 19, 47-54	
102	Current views in chronic obstructive pulmonary disease pathogenesis and management.. **2021**, 29, 1361-1373	4
101	Inflammatory Cytokines in the Pathogenesis of Pulmonary Arterial Hypertension. **2020**, 157-161	1
100	Amorphous nano-selenium quantum dots prevent pulmonary arterial hypertension through recoupling endothelial nitric oxide synthase. **2020**, 13, 3368-3385	3
99	Safflower injection inhibits pulmonary arterial remodeling in a monocrotaline-induced pulmonary arterial hypertension rat model. **2021**, 76, 27-34	1
98	Therapeutic Advances in the Management of Pulmonary Arterial Hypertension. **2020**, 1-23	
97	Role of endothelial microRNA-150 in pulmonary arterial hypertension.	
96	miR-107 inhibits PDGF-BB-induced proliferation of human pulmonary arterial smooth muscle cells and migration through targeting NOR1. **2019**, 12, 1599-1608	5
95	A crucial role of endoplasmic reticulum stress in cellular responses during pulmonary arterial hypertension. **2020**, 12, 1481-1490	6
94	Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists. **2021**, 147, 170697	1
93	Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome.	
92	Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension. **2021**, 12, 758763	2
91	The role of immune cells in pulmonary hypertension: Focusing on macrophages. **2021**, 83, 153-153	2
90	Health-related quality of life and parental depression in children with pulmonary arterial hypertension. **2021**,	0
89	Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension.. **2021**, 12, 773235	0
88	Pulmonary hypertension [illegible]eneral considerations. **2021**, 5, 30	
87	Protective Effects of Curcumin on Pulmonary Arterial Hypertension.. **2021**, 1328, 213-221	1
86	Encyclopedia of Molecular Pharmacology. **2021**, 1328-1336	

85	RAS protein activator like 2 promotes the proliferation and migration of pulmonary artery smooth muscle cell through AKT/mammalian target of Rapamycin complex 1 pathway in pulmonary hypertension.. **2022**,		1
84	Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.. **2022**, 10,		1
83	Notch4 mediates vascular remodeling via ERK/JNK/P38 MAPK signaling pathways in hypoxic pulmonary hypertension.. **2022**, 23, 6		2
82	Association between cumulative blood pressure in early adulthood and right ventricular structure and function in middle age: The CARDIA study.. **2022**,		1
81	Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.. **2022**, 17, 13		1
80	Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension.. **2022**,		0
79	An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.. **2022**,		0
78	The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on one Stone.. **2022**,		0
77	Coagulation-independent effects of thrombin and factor Xa: role of protease-activated receptors in pulmonary hypertension.. **2022**,		1
76	Metabotropic Glutamate Receptor 5 Blockade Attenuates Pathological Cardiac Remodeling in Pulmonary Arterial Hypertension.. **2022**,		
75	A Meta-analysis of the efficacy of pulmonary artery denervation in the treatment of pulmonary hypertension.. **2022**, 53, 42-50		0
74	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature Communications*, **2021**, 12, 7104	17.4	1
73	Pathologic role of peptidyl-prolyl isomerase Pin1 in pulmonary artery remodeling. **2021**, 13, 11162-11177		
72	Evaluating the Effect of Circ-Sirt1 on the Expression of SIRT1 and Its Role in Pathology of Pulmonary Hypertension.. **2022**, 31, 9636897221081479		1
71	Role of strain echocardiography in patients with hypertension.. **2022**, 28, 6		0
70	Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation.. **2022**, 1-10		0
69	Mechanosensitive channel Piezo1 is required for pulmonary artery smooth muscle cell proliferation.. **2022**,		1
68	Platelet Activation Markers in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.. **2022**, 1		1

67	Identification of the Key Pathways and Genes in Hypoxia Pulmonary Arterial Hypertension Following Intrauterine Growth Retardation.. **2022**, 9, 789736		
66	Evaluation of the presence of TRPC6 channels in human vessels: A pilot study using immunohistochemistry.. **2022**, 16, 42		1
65	Sex-Dependent Protective Effect of Combined Application of Solubilized Ubiquinol and Selenium on Monocrotaline-Induced Pulmonary Hypertension in Wistar Rats.. **2022**, 11,		1
64	Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy.. **2022**, 12, e12074		0
63	Caspase-8 Promotes Pulmonary Hypertension by Activating Macrophage-Associated Inflammation and IL-1 (Interleukin 1) Production.. **2022**, 101161ATVBAHA121317168		2
62	Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Plant With Potent Anti-SARS-CoV-2 Activity.. **2021**, 12, 742875		2
61	MSC Transplantation Attenuates Inflammation, Prevents Endothelial Damage and Enhances the Angiogenic Potency of Endogenous MSCs in a Model of Pulmonary Arterial Hypertension.. **2022**, 15, 2087-2101		0
60	Image_1.TIF. **2018**,		
59	Image_2.TIF. **2018**,		
58	Image_3.TIF. **2018**,		
57	DataSheet1.pdf. **2018**,		
56	Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.. **2022**, 12, 7803		3
55	Role of curcumin in ameliorating hypertension and associated conditions: a mechanistic insight.. **2022**, 1		0
54	An Update on Advancements and Challenges in Inhalational Drug Delivery for Pulmonary Arterial Hypertension. **2022**, 27, 3490		0
53	Notopterol Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rat. **2022**, 9,		2
52	Devemos Considerar a Estimulação da Guanilil Ciclase Solúvel como Benéfica para o Tratamento da Hipertensão Pulmonar Pré-Capilar?. *Arquivos Brasileiros De Cardiologia*, **2022**, 118, 1067-1068	1.2	
51	Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension. *Frontiers in Oncology*, 12,	5.3	
50	Target Nuclear Factor Erythroid 2-Related Factor 2 in Pulmonary Hypertension: Molecular Insight into Application. *Oxidative Medicine and Cellular Longevity*, **2022**, 2022, 1-14	6.7	0

49	TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats. *Vascular Pharmacology*, **2022**, 145, 107017	5.9	0
48	Role of NO-cGMP-PKG axis in pulmonary arterial hypertension. *Folia Pharmacologica Japonica*, **2022**, 157, 221-225	0	
47	Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. *Signal Transduction and Targeted Therapy*, **2022**, 7,	21	3
46	Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. *Acta Pharmacologica Sinica*,	8	1
45	Salt-inducible kinases: new players in pulmonary arterial hypertension?. *Trends in Pharmacological Sciences*, **2022**,	13.2	0
44	AAV-mediated gene transfer of inducible nitric oxide synthase (iNOS) to an animal model of pulmonary hypertension. *Human Gene Therapy*,	4.8	0
43	Methylation-mediated silencing of PTPRD induces pulmonary hypertension by promoting pulmonary arterial smooth muscle cell migration via the PDGFRB/PLC1 axis. *Journal of Hypertension*, Publish Ahead of Print,	1.9	0
42	Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life. *Nature Communications*, **2022**, 13,	17.4	2
41	Inhibition of KIR2.1 decreases pulmonary artery smooth muscle cell proliferation and migration. **2022**, 50,		
40	Farnesyl diphosphate synthase regulated endothelial proliferation and autophagy during rat pulmonary arterial hypertension induced by monocrotaline. **2022**, 28,		
39	Microfluidic device for recapitulating PAH-afflicted pulmonary artery: design, fabrication, and on-chip cell culture.		1
38	Microfluidic device for recapitulating PAH-afflicted pulmonary artery: design, fabrication, and on-chip cell culture.		
37	Pulmonary Hypertension Definition, Classification and Epidemiology in Asia. **2022**,		0
36	Knockdown of HSP110 attenuates hypoxia-induced pulmonary hypertension in mice through suppression of YAP/TAZ-TEAD4 pathway. **2022**, 23,		0
35	Novel predictor of pulmonary arterial hypertension: Monocyte to HDL cholesterol ratio. **2022**, 101, e29973		0
34	A Protocol for Fabrication and on-Chip Cell Culture to Recreate PAH-Afflicted Pulmonary Artery on a Microfluidic Device. **2022**, 13, 1483		1
33	DNA-PKcs participated in hypoxic pulmonary hypertension. **2022**, 23,		0
32	Lycopene Ameliorates Hypoxic Pulmonary Hypertension via Suppression of Oxidative Stress. **2022**, 2022, 1-24		0

31	Efficacy of computed tomography in diagnosing pulmonary hypertension: A systematic review and meta-analysis. 9,	0
30	Cathepsin S Inhibition Suppresses Experimental Systemic Lupus Erythematosus-Associated Pulmonary Arterial Remodeling. **2022**, 23, 12316	0
29	MircoRNA in Extracellular Vesicles from Patients with Pulmonary Arterial Hypertension Alters Endothelial Angiogenic Response. **2022**, 23, 11964	2
28	MKI67 as a potential diagnostic biomarker in pulmonary hypertension. 10,	0
27	Sex- and Gender-Related Aspects in Pulmonary Hypertension. **2023**, 19, 11-24	0
26	Pathophysiology and Pathogenic Mechanisms of Pulmonary Hypertension: Role of Membrane Receptors, Ion Channels and Ca2+ Signaling.	1
25	Deletion of classical transient receptor potential 1, 3 and 6 alters pulmonary vasoconstriction in chronic hypoxia-induced pulmonary hypertension in mice. 13,	0
24	The identification and verification of hub genes associated with pulmonary arterial hypertension using weighted gene co-expression network analysis. **2022**, 22,	0
23	Targeting integrin pathways: mechanisms and advances in therapy. **2023**, 8,	1
22	Important Role of Endogenous Nerve Growth Factor Receptor in the Pathogenesis of Hypoxia-Induced Pulmonary Hypertension in Mice. **2023**, 24, 1868	0
21	Purine synthesis suppression reduces the development and progression of pulmonary hypertension in rodent models.	0
20	Long non-coding RNAs: The growth controller of vascular smooth muscle cells in cardiovascular diseases. **2023**, 157, 106392	0
19	Pulmonary artery smooth muscle cell phenotypic switching: A key event in the early stage of pulmonary artery hypertension. **2023**, 28, 103559	0
18	Insights into circular RNAs : Biogenesis, function and their regulatory roles in cardiovascular disease.	0
17	Prognostic value of follow-up vasoreactivity test in pulmonary arterial hypertension. **2023**,	0
16	Curcumol suppresses endothelial-to-mesenchymal transition via inhibiting the AKT/GSK3β signaling pathway and alleviates pulmonary arterial hypertension in rats. **2023**, 943, 175546	0
15	Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension. **2023**, 943, 175558	0
14	Lung Dysfunction and Chronic Kidney Disease: A Complex Network of Multiple Interactions. **2023**, 13, 286	0

13	Weighted gene co-expression network analysis reveals the hub genes associated with pulmonary hypertension. **2023**, 248, 217-231	0
12	Function of sildenafil on diseases other than urogenital system: An umbrella review. 14,	0
11	Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. **2023**, 24, 3332	0
10	Protective effect of triclosan in monocrotaline-induced pulmonary arterial hypertension: FASN inhibition a novel approach. **2022**, 14, 171	0
9	Histone Methyl Transferase G9a/GLP □A Novel Avenue in PAH Treatment?.	0
8	Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial. **2023**, 24,	0
7	Perioperative Decision-Making in Pulmonary Hypertension. **2023**, 32, 454-466	0
6	The mechanism of programmed death and endoplasmic reticulum stress in pulmonary hypertension. **2023**, 9,	0
5	T18/S19 diphosphorylation of myosin regulatory light chain impairs pulmonary artery relaxation in monocrotaline-induced pulmonary hypertensive rats.	0
4	Inhibiting IL-6 in medicine: a new twist to sustain inhibition of his cytokine tin the therapy of Pulmonary Arterial Hypertension. **2023**, 106750	0
3	Untangling the mechanisms of pulmonary hypertension-induced right ventricular stiffening in a large animal model.	0
2	Cardiac Magnetic Resonance Derived Left Ventricular Eccentricity Index and Right Ventricular Mass Measurements Predict Outcome in Children with Pulmonary Arterial Hypertension. **2023**, 10, 756	0
1	GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension. **2023**, 13,	0